ProCE Banner Activity

Long-Acting Antiretrovirals: A Strategy to Support Adherence in Those With Complex Medical and Social Issues?

Clinical Thought

The JABS study documented high rates of adherence and virologic success with LA CAB + RPV as maintenance therapy in persons living with HIV with historical nonadherence.  

Released: September 06, 2023

Share

Faculty

Marta Boffito

Marta Boffito, MD, PhD, FRCP, MBA

Consultant Physician
Clinical Director
HIV, Sexual and Gender Health, Dermatology
Chelsea and Westminster Hospital NHS Foundation Trust
Imperial College London
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare.

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

ViiV Healthcare

Partners

IAS 2023

ProCE Banner

Faculty Disclosure

Primary Author

Marta Boffito, MD, PhD, FRCP, MBA

Consultant Physician
Clinical Director
HIV, Sexual and Gender Health, Dermatology
Chelsea and Westminster Hospital NHS Foundation Trust
Imperial College London
London, United Kingdom

Marta Boffito, MD, PhD, FRCP, MBA: consultant/advisor/speaker: AstraZeneca, Atea, Gilead, GlaxoSmithKline, Janssen, Merck Sharp & Doheme, Mylan, Pfizer, Roche, Teva, ViiV; researcher: Gilead, Janssen, Moderna, Mylan, Merck Sharp & Doheme, Sanofi, Valneva, ViiV.